FDA expands approved use of Stivarga to treat liver cancer

The U.S. Food and Drug Administration expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade. "Limited treatment options are available for patients ["]

The post FDA expands approved use of Stivarga to treat liver cancer appeared first on Outbreak News Today.